Having trouble accessing articles? Reset your cache.

4Q10 milestones

4Q10 milestones

Company Product Indication Event Milestone
Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) Exelbine vinorelbine emulsion (ANX-530) Non-small cell lung cancer (NSCLC) Resubmit NDA 4Q10
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)/Biovail Corp. (TSX:BVF; NYSE:BVF) Staccato loxapine (AZ-004) Agitation in patients with schizophrenia or bipolar disorder PDUFA date 10/11/10
Alimera Sciences Inc. (NASDAQ:ALIM)/ pSivida Corp. (NASDAQ:PSDV; ASX:PVA) Iluvien Diabetic macular edema (DME) FDA action 4Q10
Alkermes Inc. (NASDAQ:ALKS) Vivitrol naltrexone Opioid dependence PDUFA date 10/12/10
Allos Therapeutics Inc. (NASDAQ:ALTH) Pralatrexate Peripheral T cell lymphoma (PTCL) Submit MAA 4Q10
Almirall S.A. (Madrid:ALM)/Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)/Astellas Pharma Inc. (Tokyo:4503)/Forest Laboratories Inc. (NYSE:FRX) Linaclotide Irritable bowel syndrome with constipation (IBS-C) Ph III data 4Q10
Amgen Inc. (NASDAQ:AMGN)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) Denosumab Prevent bone metastases associated with prostate cancer Ph III data 4Q10
Amgen Inc. (NASDAQ:AMGN)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) Denosumab Bone metastases to reduce skeletal related events (SREs) in cancer patients PDUFA date 11/18/10
Amgen Inc. (NASDAQ:AMGN)/Takeda Pharmaceutical

Read the full 1980 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE